| Talimogene Laherparepvec studied in …STUDIED_INderived43 of 43show fewer |
|---|
| → studied in | NCT02923778Phase 2 · active not recruiting Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery · 43 trials list this drug (8 active) | — | — | Liposarcoma,Soft Tissue Sarcoma,Leiomyosarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02978625Phase 2 · active not recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · 43 trials list this drug (8 active) | — | — | Anaplastic Large Cell Lymphoma,Anaplastic Large Cell Lymphoma, ALK-Negative,Anaplastic Large Cell Lymphoma, ALK-Positive+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03069378Phase 2 · active not recruiting A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma · 43 trials list this drug (8 active) | — | — | Sarcoma,Epithelioid Sarcoma,Skin Angiosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06660810Phase 2 · active not recruiting Neoadjuvant Intralesional Injection of Talimogene Laherparepvec · 43 trials list this drug (8 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02965716Phase 2 · active not recruiting Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma · 43 trials list this drug (8 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07102394Phase 1 · recruiting Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 · 43 trials list this drug (8 active) | — | — | Neurofibroma,Skin Neurofibroma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02779855Phase 1/Phase 2 · completed Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer · 43 trials list this drug (8 active) | — | — | Malignant Breast Neoplasm,Invasive Breast Carcinoma,Breast Ductal Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04599062Phase 1/Phase 2 · active not recruiting TVEC and Preop Radiation for Sarcoma (8 ml Dose) · 43 trials list this drug (8 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04163952Phase 1 · terminated Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin · 43 trials list this drug (8 active) | — | — | Skin Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03802604early Phase 1 · completed Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer · 43 trials list this drug (8 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03554044Phase 1 · completed T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer · 43 trials list this drug (8 active) | — | — | Breast Carcinoma,Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02819843Phase 2 · completed A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors · 43 trials list this drug (8 active) | — | — | Melanoma,Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068181Phase 2 · completed Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03086642Phase 1 · completed Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer · 43 trials list this drug (8 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03663712Phase 1 · completed Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies · 43 trials list this drug (8 active) | — | — | Peritoneal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02509507Phase 1/Phase 2 · completed Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 · 43 trials list this drug (8 active) | — | — | Liver Neoplasm,Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02453191Phase 1/Phase 2 · completed TVEC and Preop Radiation for Sarcoma (4 ml Dose) · 43 trials list this drug (8 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03300544Phase 1 · terminated Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer · 43 trials list this drug (8 active) | — | — | Malignant Rectal Neoplasm,Rectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01740297Phase 1/Phase 2 · completed Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03256344Phase 1 · completed Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases · 43 trials list this drug (8 active) | — | — | Malignant Colorectal Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03842943Phase 2 · recruiting Neoadjuvant Combination Immunotherapy for Stage III Melanoma · 43 trials list this drug (8 active) | — | — | Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02756845Phase 1 · completed Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors · 43 trials list this drug (8 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04185311Phase 1 · terminated Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted · 43 trials list this drug (8 active) | — | — | Invasive Breast Carcinoma of No Special Type,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03064763Phase 1 · completed Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma · 43 trials list this drug (8 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02211131Phase 2 · completed Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma · 43 trials list this drug (8 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02658812Phase 2 · terminated Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery · 43 trials list this drug (8 active) | — | — | Breast Carcinoma,Malignant Chest Wall Neoplasm,Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02263508Phase 3 · terminated Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04065152Phase 2 · unknown Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma · 43 trials list this drug (8 active) | — | — | Kaposi Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02366195Phase 2 · completed Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02626000Phase 1 · completed Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) · 43 trials list this drug (8 active) | — | — | Head and Neck Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03555032Phase 1/Phase 2 · completed TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion) · 43 trials list this drug (8 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03597009Phase 1/Phase 2 · terminated A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion · 43 trials list this drug (8 active) | — | — | Malignant Neoplasm,Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03972046Phase 2 · withdrawn Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03430687Phase 1 · withdrawn Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma · 43 trials list this drug (8 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02014441Phase 2 · completed Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02297529no longer available Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00769704Phase 3 · completed Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00402025Phase 1 · completed Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer · 43 trials list this drug (8 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02147951no longer available Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01161498Phase 3 · terminated Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer · 43 trials list this drug (8 active) | — | — | Malignant Head and Neck Neoplasm,Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00289016Phase 2 · completed A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01368276Phase 3 · completed An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02574260Phase 2 · completed An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) · 43 trials list this drug (8 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |